Epigenetics of chronic inflammatory diseases

Eleni Stylianou Consultant Biomedical Scientist and Bioinformaticist, North Royalton, OH, USA Abstract: Chronic, noncommunicable, and inflammation-associated diseases remain the largest cause of morbidity and mortality globally and within the United States. This is mainly due to our limited...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Stylianou E
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Epigenetics non-resolving inflammation inflammatory diseases atherosclerosis Type 2 Diabetes Alzheimer’s disease Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/1a90a7e8614b456dad8f848e4bac8611
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1a90a7e8614b456dad8f848e4bac8611
record_format	dspace
spelling	oai:doaj.org-article:1a90a7e8614b456dad8f848e4bac86112021-12-02T05:05:28ZEpigenetics of chronic inflammatory diseases1178-7031https://doaj.org/article/1a90a7e8614b456dad8f848e4bac86112018-12-01T00:00:00Zhttps://www.dovepress.com/epigenetics-of-chronic-inflammatory-diseases-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Eleni Stylianou Consultant Biomedical Scientist and Bioinformaticist, North Royalton, OH, USA Abstract: Chronic, noncommunicable, and inflammation-associated diseases remain the largest cause of morbidity and mortality globally and within the United States. This is mainly due to our limited understanding of the molecular mechanisms that underlie these complex pathologies. The available evidence indicates that studies of epigenetics (traditionally defined as the heritable changes to gene expression that are independent of changes to DNA) are significantly advancing our knowledge of these inflammatory conditions. This review will focus on epigenetic studies of three diseases, that are among the most burdensome globally: cardiovascular disease, the number one cause of deaths worldwide, type 2 diabetes and, Alzheimer’s disease. The current status of epigenetic research, including the ability to predict disease risk, and key pathophysiological defects are discussed. The significance of defining the contribution of epigenetic defects to nonresolving inflammation and aging, each associated with these diseases, is highlighted, as these are likely to provide new insights into inflammatory disease pathogenesis. Keywords: epigenetics, nonresolving inflammation, inflammatory diseases, atherosclerosis, type 2 diabetes, Alzheimer’s diseaseStylianou EDove Medical PressarticleEpigeneticsnon-resolving inflammationinflammatory diseasesatherosclerosisType 2 DiabetesAlzheimer’s diseasePathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 12, Pp 1-14 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Epigenetics non-resolving inflammation inflammatory diseases atherosclerosis Type 2 Diabetes Alzheimer’s disease Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	Epigenetics non-resolving inflammation inflammatory diseases atherosclerosis Type 2 Diabetes Alzheimer’s disease Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Stylianou E Epigenetics of chronic inflammatory diseases
description	Eleni Stylianou Consultant Biomedical Scientist and Bioinformaticist, North Royalton, OH, USA Abstract: Chronic, noncommunicable, and inflammation-associated diseases remain the largest cause of morbidity and mortality globally and within the United States. This is mainly due to our limited understanding of the molecular mechanisms that underlie these complex pathologies. The available evidence indicates that studies of epigenetics (traditionally defined as the heritable changes to gene expression that are independent of changes to DNA) are significantly advancing our knowledge of these inflammatory conditions. This review will focus on epigenetic studies of three diseases, that are among the most burdensome globally: cardiovascular disease, the number one cause of deaths worldwide, type 2 diabetes and, Alzheimer’s disease. The current status of epigenetic research, including the ability to predict disease risk, and key pathophysiological defects are discussed. The significance of defining the contribution of epigenetic defects to nonresolving inflammation and aging, each associated with these diseases, is highlighted, as these are likely to provide new insights into inflammatory disease pathogenesis. Keywords: epigenetics, nonresolving inflammation, inflammatory diseases, atherosclerosis, type 2 diabetes, Alzheimer’s disease
format	article
author	Stylianou E
author_facet	Stylianou E
author_sort	Stylianou E
title	Epigenetics of chronic inflammatory diseases
title_short	Epigenetics of chronic inflammatory diseases
title_full	Epigenetics of chronic inflammatory diseases
title_fullStr	Epigenetics of chronic inflammatory diseases
title_full_unstemmed	Epigenetics of chronic inflammatory diseases
title_sort	epigenetics of chronic inflammatory diseases
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/1a90a7e8614b456dad8f848e4bac8611
work_keys_str_mv	AT stylianoue epigeneticsofchronicinflammatorydiseases
_version_	1718400575626805248

Epigenetics of chronic inflammatory diseases

Ejemplares similares